News

February 26, 2020February 27, 2020

Zejula as First-line Treatment for Advanced Ovarian Cancer Before FDA

News

The U.S. Food and Drug Administration (FDA) has accepted GSK‘s request to extend approval for Zejula (niraparib) to include as a first-line maintenance therapy for women with newly diagnosed ... Read more

February 24, 2020February 24, 2020

University of Sydney Given $3.75M Grant to Study Personalized Ovarian Cancer Treatments

News

The Australian Cancer Council NSW has awarded its annual $3.75 million Translational Program Grant to a University of Sydney research team to explore better ways to personalize ovarian cancer ... Read more

February 19, 2020February 19, 2020

Myriad Asks FDA to Approve myChoice CDx to Find Potential Lynparza Candidates

News

Myriad Genetics submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its myChoice CDx test to identify ovarian cancer patients likely to benefit from ... Read more

February 17, 2020February 17, 2020

Analysis of Cells in Fallopian Tube Can Help Classify Ovarian Cancer Subtypes, Study Says

News

Analysis of cells in the fallopian tube, from which most ovarian cancers develop, can help classify ovarian cancer subtypes, with potential implications for cancer prognoses and treatment strategies, a ... Read more

February 14, 2020February 14, 2020

Checkpoint Inhibitor Combination Well-tolerated, Effective in Ovarian Cancer Patients, Phase 1b Trial Shows

News

A combination of two checkpoint inhibitor therapies, magrolimab (Hu5F9-G4) and Bavencio (avelumab), has an acceptable safety profile, is well-tolerated, and stabilizes disease in more than half of heavily-treated ovarian ... Read more

February 12, 2020February 26, 2020

New Trial Data Continue to Support DPX-Survivac in Treating Advanced Ovarian Cancer

News

Immune responses in women with advanced ovarian cancer being treated with DPX-Survivac in clinical trials continue to support the immunotherapy’s potential, alone or in combination, to be effective in this patient population. ... Read more

February 10, 2020February 10, 2020

France Adds Rubraca for Relapsed Platinum-sensitive Ovarian Cancer to Reimbursed Treatments

News

Rubraca (rucaparib) is now available in France and eligible for reimbursement when used as a maintenance therapy by women with relapsed ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA status, its ... Read more

February 7, 2020February 7, 2020

New Progress Made in Developing Bio-ink for 3-D Printing Functional Human Ovaries, Researchers Report

News

Researchers at Northwestern University have identified and mapped the location of structural proteins within pig’s ovaries, which closely resemble human ovaries. This will help the development of an ovary-specific ... Read more

January 31, 2020January 31, 2020

Nami Developing Targeted Nanoparticle Therapy for Advanced Forms of Ovarian Cancer

News

Nami Therapeutics is developing a new form of targeted therapy that aims to be more effective and less toxic than other treatments for advanced forms of ovarian cancer. The ... Read more

January 30, 2020February 5, 2020

Clinical Trial of DNA Decoy to Make Ovarian Cancer’s Zejula More Effective Set to Open

News

A Phase 1b/2 clinical trial testing Onxeo’s AsiDNA as a potential treatment to overcome resistance to Zejula (niraparib) in ovarian cancer patients is set to begin, part of an ... Read more

Pin It on Pinterest